Table 1.
Selected patient and tumor characteristics
| Gefitinib N = 28 | Erlotinib N = 31 | ||||
|---|---|---|---|---|---|
| Age (at diagnosis) |
Median (range) |
63.5 (37–80) |
65.8 (34–79) |
||
| |
|
N |
% |
N |
% |
| Gender |
Male |
20 |
71 |
20 |
65 |
| |
Female |
8 |
29 |
11 |
35 |
| Smoker |
No |
7 |
25 |
12 |
39 |
| |
Yes |
20 |
71 |
16 |
52 |
| |
Unknown |
1 |
4 |
3 |
10 |
| Histology |
Squamous cell Ca |
4 |
14 |
3 |
10 |
| |
Adenocarcinoma |
18 |
64 |
22 |
71 |
| |
Large cell Ca |
1 |
4 |
- |
- |
| |
Mixed type Ca |
1 |
4 |
1 |
3 |
| |
Undifferentiated/Unclassified Ca |
3 |
11 |
2 |
6 |
| |
Unknown |
1 |
4 |
3 |
10 |
| Grade |
1 |
3 |
11 |
2 |
6 |
| |
2 |
4 |
14 |
7 |
23 |
| |
3 |
6 |
21 |
6 |
19 |
| |
Undifferentiated |
3 |
11 |
- |
- |
| |
Unknown |
12 |
43 |
16 |
52 |
| Performance status |
0 |
6 |
21 |
7 |
23 |
| |
1 |
15 |
54 |
16 |
52 |
| |
2 |
- |
- |
1 |
3 |
| |
Unknown |
7 |
25 |
7 |
23 |
| Line of TKI treatment |
1st |
4 |
14 |
9 |
29 |
| |
2nd |
18 |
64 |
15 |
48 |
| >2nd | 6 | 21 | 7 | 22 | |